Investing.com - Fulgent Genetics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Fulgent Genetics announced earnings per share of $0.06 on revenue of $105.66M. Analysts polled by Investing.com EPS of $0.17 on revenue of $103.7M.
Fulgent Genetics 's are up 6% and is trading at $32.03 , still down 67.58% from its 52 week high of $109.55 set on Monday, December 20, 2021.
Fulgent Genetics shares lost 9.83% to trade at $32.03 in after-hours trade the report.
Fulgent Genetics follows other major Healthcare sector earnings this month
Fulgent Genetics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar